Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 121

Inclusion Criteria

1. Male and female patients =12 years of age with HoFH. Patients aged =12 years old will be enrolled only in countries where permitted by the Regulatory Agency and Institutional Review Board (IRB) or Ethics Committee (EC).
2. Diagnosis of functional HoFH by at least 1 of the following genetic or clinical criteria:
a. Documented functional mutation or mutations in both LDLR alleles
Note: patients who have null receptor mutations on both LDLR alleles, ie, double null, are eligible
b. Presence of homozygous or compound heterozygous mutations in Apo B or PCSK9
Note: patients who are double heterozygous, ie, mutations on different genes (eg, LDLR/PCSK9) and patients with homozygous LDLRAP1 mutations are eligible
c. Untreated TC >500 mg/dL (12.93 mmol/L) and TG <300 mg/dL (3.39 mmol/L) AND both parents with documented TC >250 mg/dL (6.47 mmol) OR cutaneous or tendinous xanthoma before the age of 10 years
3. For patients who have participated in a previous evinacumab or alirocumab study: completion of the study in which they participated.
4. Willing and able to comply with clinic visits and study-related procedures.
5. Provide signed informed consent.

Are the trial subjects under 18? yes
Number of subjects for this age range: 9
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 112
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Exclusion Criteria for Evinacumab-Naïve Patients
1. Concomitant medications and procedures that have not been stable prior to the baseline visit
2. Any new condition or worsening of an existing condition, which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
3. History of a MI, unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, valve replacement surgery, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the baseline visit
4. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins
5. Newly diagnosed (within 3 months prior to screening visit diabetes mellitus or poorly controlled (HbA1c >9%) diabetes
6. Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to screening visit
7. Use of estrogen or testosterone therapy unless the regimen has been stable 6 weeks prior to the screening visit and no plans to change the regimen during the study
8. Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at the screening visit
9. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
10. History of New York Heart Association (NYHA) Class IV heart failure within 12 months before screening
11. Laboratory findings during the screening period (applies to patients undergoing Screening):
• Alanine aminotransferase or aspartate aminotransferase >3 x upper limit of normal (ULN)(1 repeat lab is allowed)
• CPK >3 x ULN (1 repeat lab is allowed)
• Positive serum beta-human chorionic gonadotropin or urine pregnancy test in WOCBP
• TSH >1.5 x ULN of the central laboratory (1 repeat lab is allowed) for patients not on thyroid replacement therapy
• Positive test for hepatitis B surface antigen and/or hepatitis C antibody (associated with a positive HCV RNA polymerase chain reaction)
• eGFR <30 mL/min/1.73 m2 (calculated by central lab)
• Postmenopausal status will be confirmed by measurement of follicle-stimulating hormone (FSH)
12. Member of the clinical site study team and/or his/her immediate family.
13. Pregnant of breastfeeding women
14. Women of child bearing potential (see protocol for more information)
15. Men who are sexually active with WOCBP and are unwilling to use the following forms of medically acceptable birth control during the study drug treatment period and for 24 weeks after the last injection of study drug: vasectomy with medical assessment of surgical success OR consistent use of a condom. Sperm donation is prohibited during the study and for up to 24 weeks after the last injection of study drug.
16. LDL-C level <70 mg/dL at screening visit
17. Use of any active investigational drugs (except alirocumab) within 1 month or 5 half lives prior to the screening visit, whichever is longer.
18. Age <12 years at the screening visit
19. Tanner stage <2 at the screening visit

Exclusion Criteria for Patients from a Previous Evinacumab Study
1. Significant protocol deviation in the previous study

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials